Systolic blood pressure responses to enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) and hydrochlorothiazide in conscious Dahl salt-sensitive and salt-resistant rats

J. N. Sharma, P. G. Fernandez, B. K. Kim, Christopher Triggle

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Systolic blood pressure responses to enalapril maleate (MK 421, a new angiotensin converting enzyme inhibitor (CEI) and hydrochlorothiazide (HTZ) were studied in conscious Dahl salt-sensitive (DS) and salt-resistant (DR) rats maintained on a high salt (8.0% NaCl) and a normal salt (0.4% NaCl) diet. The DS rats were severely hypertensive after 3 weeks on the high salt diet whereas the systolic blood pressure (SBP) of the DR rats were normotensive. Oral treatment with enalapril (15-100 mg.kg-1.day-1) and HTZ (60-400 mg.kg-1.day-1) caused a significant reduction of SBP in the DS rats with the high salt diet (P < 0.001); however, this was not observed until after 4 weeks of treatment when the dosage was 30 and 150 mg/kg-1.day-1, respectively. Furthermore, enalapril therapy alone significantly reduced the SBP of all groups of rats regardless of diet or Dahl strain (P < 0.001), but this was not observed until the end of the 7th week of therapy in DR rats on 8.0% NaCl and at the end of the 3rd week of therapy for DR and DS rats on 0.4% NaCl. These results suggest that enalapril may lower SBP by mechanisms other than those related to an action as a CEI.

Original languageEnglish
Pages (from-to)846-849
Number of pages4
JournalCanadian Journal of Physiology and Pharmacology
Volume62
Issue number7
Publication statusPublished - 1984
Externally publishedYes

Fingerprint

Enalapril
Hydrochlorothiazide
Angiotensin-Converting Enzyme Inhibitors
Salts
Blood Pressure
Inbred Dahl Rats
Diet
Enzyme Inhibitors
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Physiology
  • Pharmacology
  • Physiology (medical)

Cite this

@article{eed6bc3bc86e4c0ba6a8a03bc553d728,
title = "Systolic blood pressure responses to enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) and hydrochlorothiazide in conscious Dahl salt-sensitive and salt-resistant rats",
abstract = "Systolic blood pressure responses to enalapril maleate (MK 421, a new angiotensin converting enzyme inhibitor (CEI) and hydrochlorothiazide (HTZ) were studied in conscious Dahl salt-sensitive (DS) and salt-resistant (DR) rats maintained on a high salt (8.0{\%} NaCl) and a normal salt (0.4{\%} NaCl) diet. The DS rats were severely hypertensive after 3 weeks on the high salt diet whereas the systolic blood pressure (SBP) of the DR rats were normotensive. Oral treatment with enalapril (15-100 mg.kg-1.day-1) and HTZ (60-400 mg.kg-1.day-1) caused a significant reduction of SBP in the DS rats with the high salt diet (P < 0.001); however, this was not observed until after 4 weeks of treatment when the dosage was 30 and 150 mg/kg-1.day-1, respectively. Furthermore, enalapril therapy alone significantly reduced the SBP of all groups of rats regardless of diet or Dahl strain (P < 0.001), but this was not observed until the end of the 7th week of therapy in DR rats on 8.0{\%} NaCl and at the end of the 3rd week of therapy for DR and DS rats on 0.4{\%} NaCl. These results suggest that enalapril may lower SBP by mechanisms other than those related to an action as a CEI.",
author = "Sharma, {J. N.} and Fernandez, {P. G.} and Kim, {B. K.} and Christopher Triggle",
year = "1984",
language = "English",
volume = "62",
pages = "846--849",
journal = "Canadian Journal of Physiology and Pharmacology",
issn = "0008-4212",
publisher = "National Research Council of Canada",
number = "7",

}

TY - JOUR

T1 - Systolic blood pressure responses to enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) and hydrochlorothiazide in conscious Dahl salt-sensitive and salt-resistant rats

AU - Sharma, J. N.

AU - Fernandez, P. G.

AU - Kim, B. K.

AU - Triggle, Christopher

PY - 1984

Y1 - 1984

N2 - Systolic blood pressure responses to enalapril maleate (MK 421, a new angiotensin converting enzyme inhibitor (CEI) and hydrochlorothiazide (HTZ) were studied in conscious Dahl salt-sensitive (DS) and salt-resistant (DR) rats maintained on a high salt (8.0% NaCl) and a normal salt (0.4% NaCl) diet. The DS rats were severely hypertensive after 3 weeks on the high salt diet whereas the systolic blood pressure (SBP) of the DR rats were normotensive. Oral treatment with enalapril (15-100 mg.kg-1.day-1) and HTZ (60-400 mg.kg-1.day-1) caused a significant reduction of SBP in the DS rats with the high salt diet (P < 0.001); however, this was not observed until after 4 weeks of treatment when the dosage was 30 and 150 mg/kg-1.day-1, respectively. Furthermore, enalapril therapy alone significantly reduced the SBP of all groups of rats regardless of diet or Dahl strain (P < 0.001), but this was not observed until the end of the 7th week of therapy in DR rats on 8.0% NaCl and at the end of the 3rd week of therapy for DR and DS rats on 0.4% NaCl. These results suggest that enalapril may lower SBP by mechanisms other than those related to an action as a CEI.

AB - Systolic blood pressure responses to enalapril maleate (MK 421, a new angiotensin converting enzyme inhibitor (CEI) and hydrochlorothiazide (HTZ) were studied in conscious Dahl salt-sensitive (DS) and salt-resistant (DR) rats maintained on a high salt (8.0% NaCl) and a normal salt (0.4% NaCl) diet. The DS rats were severely hypertensive after 3 weeks on the high salt diet whereas the systolic blood pressure (SBP) of the DR rats were normotensive. Oral treatment with enalapril (15-100 mg.kg-1.day-1) and HTZ (60-400 mg.kg-1.day-1) caused a significant reduction of SBP in the DS rats with the high salt diet (P < 0.001); however, this was not observed until after 4 weeks of treatment when the dosage was 30 and 150 mg/kg-1.day-1, respectively. Furthermore, enalapril therapy alone significantly reduced the SBP of all groups of rats regardless of diet or Dahl strain (P < 0.001), but this was not observed until the end of the 7th week of therapy in DR rats on 8.0% NaCl and at the end of the 3rd week of therapy for DR and DS rats on 0.4% NaCl. These results suggest that enalapril may lower SBP by mechanisms other than those related to an action as a CEI.

UR - http://www.scopus.com/inward/record.url?scp=0021181738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021181738&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 846

EP - 849

JO - Canadian Journal of Physiology and Pharmacology

JF - Canadian Journal of Physiology and Pharmacology

SN - 0008-4212

IS - 7

ER -